Puriblood Medical Co., Ltd.
6847.TWO
Taipei Exchange80.50
TWD
+0.50
- -
Puriblood Medical Co., Ltd.
6847.TWO
(Taipei Exchange)
Recent
price
80.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Puriblood Medical Co., Ltd. Puriblood Medical Co., Ltd. (6847.TWO) develops and sells advanced blood cell separation and filtration products utilizing proprietary Zwitterionic-bias Surface Coating Technology (ZISC technology) for medical and research applications in the healthcare sector; its core offerings include leukocyte reduction filters for red blood cells, platelets, and whole blood; real-time filtration sets for whole blood; Devin blood fractionation membrane filters; and Minipuri cell screening syringe filters such as the SFLR-P series designed for white blood cell removal from platelet-rich plasma (PRP) or platelet samples with high filtration speed, over 99.9% leukocyte reduction, over 95% red blood cell recovery, minimal volume loss, and low hemolysis even at low temperatures like 4 degrees Celsius. The company targets hospitals, blood banks, clinicians, and research institutions requiring safe transfusion and cell separation solutions for human and animal blood applications, operating primarily from its headquarters at 2F, No. 11 Gongye East 9th Road, Baoshan Township, Hsinchu City, Taiwan, where it was founded in 2016 by Dr. Yung Chang in conjunction with the R&D Center for Membrane Technology (RDCMT), holding over 36 patents supporting its membrane-based innovations. Puriblood Medical emphasizes leadership in product innovation, extensive clinician collaborations, stable quality assurance, and customized cell separation products, listing on the Taipei Exchange (TPEX) in November 2021 as a key milestone in its growth trajectory while continuing to expand its global presence in leukocyte reduction and blood purification markets through ongoing R&D and partnerships with international medical entities.